BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 9817027)

  • 1. Src homology-2 domains: structure, mechanisms, and drug discovery.
    Sawyer TK
    Biopolymers; 1998; 47(3):243-61. PubMed ID: 9817027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signal transduction drug discovery: targets, mechanisms and structure-based design.
    Dalgarno DC; Metcalf CA; Shakespeare WC; Sawyer TK
    Curr Opin Drug Discov Devel; 2000 Sep; 3(5):549-64. PubMed ID: 19649883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein-tyrosine phosphatases: structure, mechanism, and inhibitor discovery.
    Burke TR; Zhang ZY
    Biopolymers; 1998; 47(3):225-41. PubMed ID: 9817026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphoryltyrosyl mimetics in the design of peptide-based signal transduction inhibitors.
    Burke TR; Yao ZJ; Liu DG; Voigt J; Gao Y
    Biopolymers; 2001; 60(1):32-44. PubMed ID: 11376431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydrophobic D-amino acids in the design of peptide ligands for the pp60src SH2 domain.
    Plummer MS; Lunney EA; Para KS; Prasad JV; Shahripour A; Singh J; Stankovic CJ; Humblet C; Fergus JH; Marks JS; Sawyer TK
    Drug Des Discov; 1996 Apr; 13(3-4):75-81. PubMed ID: 8874045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SH2 and PTB domains in tyrosine kinase signaling.
    Schlessinger J; Lemmon MA
    Sci STKE; 2003 Jul; 2003(191):RE12. PubMed ID: 12865499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of phosphotyrosine recognition by the SH2 domain of the Src kinase.
    Bradshaw JM; Mitaxov V; Waksman G
    J Mol Biol; 1999 Nov; 293(4):971-85. PubMed ID: 10543978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specificity of the SH2 domains of SHP-1 in the interaction with the immunoreceptor tyrosine-based inhibitory motif-bearing receptor gp49B.
    Wang LL; Blasioli J; Plas DR; Thomas ML; Yokoyama WM
    J Immunol; 1999 Feb; 162(3):1318-23. PubMed ID: 9973385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-O-(2-malonyl)tyrosine: a new phosphotyrosyl mimetic for the preparation of Src homology 2 domain inhibitory peptides.
    Ye B; Akamatsu M; Shoelson SE; Wolf G; Giorgetti-Peraldi S; Yan X; Roller PP; Burke TR
    J Med Chem; 1995 Oct; 38(21):4270-5. PubMed ID: 7473554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A protein-tyrosine phosphatase with sequence similarity to the SH2 domain of the protein-tyrosine kinases.
    Shen SH; Bastien L; Posner BI; Chrétien P
    Nature; 1991 Aug; 352(6337):736-9. PubMed ID: 1652101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crystal structures of the human p56lck SH2 domain in complex with two short phosphotyrosyl peptides at 1.0 A and 1.8 A resolution.
    Tong L; Warren TC; King J; Betageri R; Rose J; Jakes S
    J Mol Biol; 1996 Mar; 256(3):601-10. PubMed ID: 8604142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteins with SH2 and SH3 domains couple receptor tyrosine kinases to intracellular signalling pathways.
    Pawson T; Olivier P; Rozakis-Adcock M; McGlade J; Henkemeyer M
    Philos Trans R Soc Lond B Biol Sci; 1993 Jun; 340(1293):279-85. PubMed ID: 8103930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors to the Src SH2 domain: a lesson in structure--thermodynamic correlation in drug design.
    Henriques DA; Ladbury JE
    Arch Biochem Biophys; 2001 Jun; 390(2):158-68. PubMed ID: 11396918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporation of phosphotyrosyl mimetic 4-(phosphonodifluoromethyl)phenylalanine (F2Pmp) into signal transduction-directed peptides.
    Yao ZJ; Lee K; Burke TR
    Methods Mol Biol; 2005; 298():91-103. PubMed ID: 16044542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SH2 domains: role, structure and implications for molecular medicine.
    Waksman G; Kumaran S; Lubman O
    Expert Rev Mol Med; 2004 Jan; 6(3):1-18. PubMed ID: 14987415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A SHPing tale: perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the C-terminal tail.
    Poole AW; Jones ML
    Cell Signal; 2005 Nov; 17(11):1323-32. PubMed ID: 16084691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of tetrapeptide ligands as inhibitors of the Src SH2 domain.
    Nam NH; Pitts RL; Sun G; Sardari S; Tiemo A; Xie M; Yan B; Parang K
    Bioorg Med Chem; 2004 Feb; 12(4):779-87. PubMed ID: 14759738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Signal transduction through SH2, SH3 and PH domains].
    Miki H
    Tanpakushitsu Kakusan Koso; 1997 Jul; 42(10 Suppl):1484-93. PubMed ID: 9279072
    [No Abstract]   [Full Text] [Related]  

  • 19. Peptidyl aldehydes as reversible covalent inhibitors of SRC homology 2 domains.
    Park J; Fu H; Pei D
    Biochemistry; 2003 May; 42(17):5159-67. PubMed ID: 12718560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular dynamics simulations on the free and complexed N-terminal SH2 domain of SHP-2.
    Wieligmann K; Pineda De Castro LF; Zacharias M
    In Silico Biol; 2002; 2(3):305-11. PubMed ID: 12542415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.